Treatment for diabetes

• US 20060234373A1
• Filed: 05/27/2003
• Published: 10/19/2006
• Est. Priority Date: 05/24/2002
• Status: Abandoned Application

• Current Assignee: Waratah Pharmaceuticals, Inc. (Opko Health, Inc.), University of Alberta
• Original Assignee: Waratah Pharmaceuticals, Inc. (Opko Health, Inc.)
• Inventors: Rabinovitch, Alex, Suarez-Pinzon, Wilma Lucia, Cruz, Antonio
• Application Number:
  US10/515,772
• Publication Number:
  US 20060234373A1
• Time in Patent Office: Days
• US Class Current: 435/325
• CPC Class Codes: A01K 2267/0362 Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
• CPC Class Codes: A01K 67/0271 Chimeric vertebrates, e.g. comprising exogenous cells
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/2207 Gastrins; Cholecystokinins [CCK]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/148 Transforming growth factor alpha [TGF-a]
• CPC Class Codes: C12N 2501/345 Gastrin; Cholecystokinins [CCK]
• CPC Class Codes: C12N 5/0676 Pancreatic cells
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/507 Pancreatic cells
• CPC Class Codes: G01N 33/5073 Stem cells
• CPC Class Codes: G01N 33/5088 of vertebrates

Abstract

Proliferating pancreatic islet cells obtained by the method of isolating a population of cells that preferably includes predominantly islet precursor cells that express one or more marker associated with an islet precursor cell and providing the precursor cells with one or more a pancreatic differentiation agent so that a population of cells is obtained that has a high proportion of cells with phenotypic characteristics of functional pancreatic islet β-cells. Optionally, the precursor cells are pretreated by providing them with one or more cell expansion agent to increase the number of cells in the population prior to differentiation. The pancreatic differentiation agent composition comprises a gastrin/CCK receptor ligand, e.g., a gastrin, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The cell expansion agent composition comprises one or more epidermal growth factor (EGF) receptor ligand in an amount sufficient to stimulate proliferation of the precursor cells. The methods of treatment include transplanting either undifferentiated precursor cells and providing the pancreatic differentiation agent either alone or in combination with the cell expansion agent in situ, or transplanting the functional pancreatic islet β-cells into the patient. The pancreatic islet β-cells can be used for drug screening, and replenishing pancreatic function in the context of clinical treatment.

Claims

1. A method for obtaining mammalian pancreatic cells comprising a plurality of functional mature β

-cells, said method comprising;

providing a population of precursor mammalian pancreatic cells with at least one gastrin receptor ligand in an amount sufficient to effect differentiation of said precursor mammalian pancreatic cells, wherein said population of precursor mammalian pancreatic cells is enriched in cells that express at least one marker associated with precursor mammalian pancreatic cells, whereby a plurality of functional mature β

-cells are obtained.

3. The method according to claim 1, wherein said population of precursor mammalian pancreatic cells is enriched in cells that express at least one marker associated with precursor mammalian pancreatic cells by FACS.

4. The method according to claim 1, wherein said population of precursor mammalian pancreatic cells comprises a plurality of stem cells or ductal epithelial cells.

5. The method according to claim 4, wherein said stem cells comprise cells from one or more source selected from the group consisting of umbilical cords, embryos, and established stem cell lines.

6. The method according to claim 4, wherein one or more islets comprise said ductal epithelial cells.

7. The method according to claim 1, wherein said population of precursor mammalian pancreatic cells has been immortalized.

8. The method according to claim 1, wherein said population of precursor mammalian pancreatic cells is provided with at least one EGF receptor ligand in an amount sufficient to effect expansion of the population of said precursor mammalian pancreatic cells.

2. The method according to claim 2, wherein said marker is CK19.

9. A method for obtaining a population of mammalian pancreatic cells comprising a plurality of functional mature β

-cells, said method comprising;

providing a population of precursor mammalian pancreatic cells expressing at least one marker associated with precursor mammalian pancreatic cells with at least one gastrin receptor ligand in an amount sufficient to effect differentiation of said precursor mammalian pancreatic cells, wherein about 10% to about 20% of said cells express said marker, whereby a plurality of functional mature β

-cells are obtained.

10. The method according to claim 9, wherein said cells are provided with at least one EGF receptor ligand in an amount sufficient to induce expansion of said population of functional mature β

-cells by about 2-fold to about 5-fold.

11. The method according to claim 10, wherein expansion is about 3-fold to about 4-fold.

12. The method according to claim 9, wherein said providing is in vitro and said amount of said EGF receptor ligand is about 0.1 μ

g/ml to about 1.0 μ

g/ml and said amount of said gastrin receptor ligand is about 0.5 μ

g/ml to about 3 μ

g/ml.

13. The method according to claim 9, wherein said providing is in vitro and said amount of said EGF receptor ligand is about 0.2 μ

g/ml to about 0.5 μ

g/ml and said amount of said gastrin receptor ligand is about 0.6 μ

g/ml to about 1.5 μ

g/ml.

14. The method according to claim 9, wherein said plurality of functional mature β

-cells express PDX-1.

15. The method according to claim 9, wherein precursor mammalian pancreatic cells are human or porcine.

16. The method according to claim 9, wherein the gastrin receptor ligand is human gastrin 1-17/Leu15.

17. The method according to claim 10, wherein the EGF receptor ligand is human EGF51N.

18. A composition comprising:

a cell culture comprising a plurality of proliferating mature pancreatic β

cells, wherein said proliferating pancreatic β

cells are obtained by the method of providing at least one gastrin receptor ligand and at least one EGF receptor ligand, and wherein said cell culture is enriched in CK19 ductal cells and have increased expression of PDX-1 as compared to cells not provided with a gastrin receptor ligand and an EGF receptor ligand.

19. A population of mammalian pancreatic precursor cells enriched to contain at least 20% precursor cell expressing CK19.

20. A method for screening for a compound that stimulates islet cell differentiation, said method comprising:

providing a population of mammalian pancreatic precursor cells with said compound and optionally at least one EGF receptor ligand; and

detecting expression of PDX-1 as an indication that said compound effects islet cell differentiation.